Clinical trial · Observational
Ovarian Cancer Individualized Scoring System Scoring System
Ovarian Cancer Individualized Scoring System (OCISS) for Prediction of Ovarian Cancer Prognosis
NCT05496517CI-TRIAL-00060257OCISSunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project aims at creating an individualized prognostic model using patient characteristics and disease features to determine disease prognosis using machine learning technology. The model can be used to determine the optimal management plan per patient in priori and highlight risk and timing of disease recurrence.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Cancer-specific survival (CSS) rate at 5 years
- timeFrame
- Within 5 years after diagnosis of ovarian cancer
- description
- Percentage of women newly diagnosed with ovarian cancer who do not die from ovarian cancer after 5 years
- measure
- Cancer-specific survival (CSS) rate at 3 years
- timeFrame
- Within 3 years after diagnosis of ovarian cancer
- description
- Percentage of women newly diagnosed with ovarian cancer who do not die from ovarian cancer after 3 years
Secondary outcomes (2)
- measure
- Recurrence-free survival (RFS) rate at 5 years
- timeFrame
- Within 5 years of diagnosis of ovarian cancer
- description
- Percentage of newly diagnosed women who do not experience disease recurrence during follow-up
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Women diagnosed with ovarian cancer between January 2010 and December 2016. * Primary non-recurrent diagnosis of ovarian cancer. * Women should be diagnosed and managed by the corresponding center. * Patients with adequate clinical and pathological data Exclusion Criteria: * • Inadequate information and follow-up for at least 5 years. * Authorization to use anonymous patient data for research purposes.
References
Publications (10)
- BACKGROUNDSung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID 33538338
- BACKGROUNDCaan BJ, Thomson CA. Breast and ovarian cancer. Optim Women's Heal through Nutr. Published online 2007:229-263. doi:10.1369/0022155411428469
- BACKGROUNDUrban N. Early detection of ovarian cancer: Methodological considerations. Int J Gynecol Obstet. 2000;70:D9-D9. doi:10.1016/s0020-7292(00)82512-6
- BACKGROUNDJacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004 Apr;3(4):355-66. doi: 10.1074/mcp.R400006-MCP200. Epub 2004 Feb 5. PMID 14764655
- BACKGROUNDGoff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004 Jun 9;291(22):2705-12. doi: 10.1001/jama.291.22.2705. PMID 15187051
- BACKGROUNDJordan SJ, Green AC, Whiteman DC, Webb PM; Australian Ovarian Cancer Study Group. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum? Gynecol Oncol. 2007 Nov;107(2):223-30. doi: 10.1016/j.ygyno.2007.06.006. Epub 2007 Jul 27. PMID 17662378
- BACKGROUNDMomenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019 Apr 30;11:287-299. doi: 10.2147/IJWH.S197604. eCollection 2019. PMID 31118829
- BACKGROUNDSalvo G, Odetto D, Pareja R, Frumovitz M, Ramirez PT. Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: A review of gaps and questions that remain. Int J Gynecol Cancer. 2020 Jun;30(6):873-878. doi: 10.1136/ijgc-2020-001257. Epub 2020 Apr 1.